Hutchison China Meditech Limited Chi-Med to Announce 2019 Half-Year Results (3198E)

TIDMHCM

RNS Number : 3198E

Hutchison China Meditech Limited

03 July 2019

Chi-Med to Announce 2019 Half-Year Financial Results

London: Wednesday, July 3, 2019: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2019 on Tuesday, July 30, 2019 at 7:00 am British Summer Time (BST) (2:00 pm Hong Kong Time (HKT); 2:00 am Eastern Daylight Time (EDT)).

An analyst presentation will be held at 9:00 am BST (4:00 pm HKT) on the same day at Citigate Dewe Rogerson, 8th Floor, Holborn Gate, 26 Southampton Buildings, London WC2A 1AN, UK, which will be webcast via the company website at www.chi-med.com/investors/event-information/. The presentation will be available to download before the analyst presentation begins.

For North America based analysts and investors, Chi-Med will also host a conference call with Q&A at 9:00 am EDT (2:00 pm BST).

Details of the analyst presentation and conference call dial-in will be provided in the financial results announcement. A replay will also be available on the website shortly after each event.

About Chi-Med

Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 440 scientists and staff focusing on discovering, developing and commercializing targeted therapeutics and immunotherapies in oncology and autoimmune diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world. Chi-Med's Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.

Chi-Med is headquartered in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com.

CONTACTS

 
Investor Enquiries 
  Mark Lee, Senior Vice President, Corporate Finance & Development      +852 2121 8200 
  Annie Cheng, Vice President, Corporate Finance & Development          +1 (973) 567 3786 
  David Dible, Citigate Dewe Rogerson                                   +44 7967 566 919 (Mobile) 
                                                                        david.dible@citigatedewerogerson.com 
  Xuan Yang, Solebury Trout                                             +1 (415) 971 9412 (Mobile) 
                                                                         xyang@troutgroup.com 
 
Media Enquiries 
  UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson                +44 7973 611 888 (Mobile) 
                                                                         anthony.carlisle@cdrconsultancy.co.uk 
  Americas - Brad Miles, Solebury Trout                                 +1 (917) 570 7340 (Mobile) 
                                                                         bmiles@troutgroup.com 
  Hong Kong & Asia ex-China          - Joseph Chi Lo, Brunswick         +852 9850 5033 (Mobile) 
                                                                         jlo@brunswickgroup.com 
                                     - Zhou Yi, Brunswick               +852 9783 6894 (Mobile) 
                                                                         yzhou@brunswickgroup.com 
  Mainland China - Sam Shen, Edelman                                    +86 136 7179 1029 (Mobile) 
                                                                         sam.shen@edelman.com 
 
Nominated Advisor 
  Richard Gray / Atholl Tweedie, Panmure Gordon (UK) Limited            +44 (20) 7886 2500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORCKNDBPBKKPOK

(END) Dow Jones Newswires

July 03, 2019 02:00 ET (06:00 GMT)

Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024